Creative Biolabs has introduced the TABK antibody, a dual-function multi-engager designed to simultaneously target NK cell checkpoints and tumor cells. This breakthrough, led by Dr. Bruce Walcheck, has attracted significant attention from the scientific community for its potential to transform cancer treatment.
The development of advanced therapeutic antibodies relies on high-quality cell lines, which serve as the foundation for biologics production. Creative Biolabs offers a comprehensive service package that includes commercial licensing of host cells, mammalian cell line development, and stability evaluation services. These services ensure efficient and customized production of monoclonal antibodies and other biologic modalities for the biotechnology and pharmaceutical industries.
The mammalian cell line development platform at Creative Biolabs is particularly notable for producing cell lines with high yield, stability, and human-specific post-translational modifications. Additionally, the company provides essential stability evaluation services, including genetic and functional stability assessments, to guarantee cell line integrity before use in research. These services are crucial for maintaining the quality and safety of cell banks in the rapidly evolving biotech landscape.
Creative Biolabs will participate in upcoming global summits where industry leaders discuss oligonucleotides, bispecific antibodies, exosome-based therapeutics, and more. These events offer opportunities for knowledge exchange and collaboration in antibody engineering and therapeutics.
The introduction of the TABK antibody and comprehensive cell line services underscores Creative Biolabs' leadership in the biotech sector and paves the way for future innovations in antibody therapy. By addressing critical challenges in cancer treatment and biologics development, the company contributes to advancing medical science and improving patient outcomes worldwide.
